Table 1 Patient characteristics
Intervention group n = 31 (%) | Non‐intervention group n = 39 (%) | P-value | |
|---|---|---|---|
Age | 70 | 67 | 0.578 |
Range | 51-86 | 28-88 | |
Gender | 1.000 | ||
Male | 27(87.1) | 35(89.7) | |
Female | 4(12.9) | 4(10.3) | |
ECOG PS | 0.645 | ||
0 | 17(54.8) | 17(43.6) | |
1 | 12(38.7) | 19(48.7) | |
2 | 2(6.45) | 3(7.7) | |
Diagnosis | 0.001* | ||
HCC | 31(100) | 27(69.2) | |
RCC | - | 12(30.8) | |
Child-Pugh classification | 0.233 | ||
A | 29(93.5) | 22(81.5) | |
B | 2(6.5) | 5(18.5) | |
Previous therapy | |||
HCC | 0.186 | ||
None | 7(22.6) | 2(7.4) | |
TACE | 20(64.5) | 22(81.5) | |
HAIC | 10(32.3) | 3(11.1) | |
RFA | 10(32.3) | 13(48.1) | |
TAI | 1(3.2) | 1(3.7) | |
Surgery | 8(25.8) | 3(11.1) | |
Molecular-targeted therapy | 2(6.5) | - | |
RCC | 0.001* | ||
None | 3(25.0) | ||
RFA | - | 1(8.3) | |
Interferon, Interleukin | - | 5(41.7) | |
Surgery | - | 7(58.3) | |
Molecular-targeted therapy | - | 4(33.3) | |
Metastatic site | |||
HCC | 0.672 | ||
Lung | 9(29.0) | 4(14.8) | |
Lymph node | 9(29.0) | 3(11.1) | |
Bone | 3(9.7) | 1(3.7) | |
Other | 4(12.9) | 4(14.8) | |
RCC | 0.001* | ||
Lung | - | 5(41.7) | |
Lymph node | - | 4(33.3) | |
Bone | - | 4(33.3) | |
Liver | - | 3(25.0) | |
Other | - | 6(50.0) |